Cannabis-based medicine for hard-to-treat seizures
Part of Brain & nervous system, Mental health clinical trials.
This study tests whether a cannabis-based medicine can reduce seizures in people with epilepsy that hasn't improved with other treatments. It may offer a new option for those who continue to have seizures.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 2 and 55 years old.
- You have epilepsy that hasn't improved after trying at least two seizure medicines.
- You have at least 4 seizures per month.
- You must agree not to drive or use recreational cannabis during the study.
- If you can become pregnant, you must use effective birth control and have a negative pregnancy test.
- You cannot have certain other conditions like severe heart, kidney, or liver disease, or a history of psychosis.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial provides access to cannabidiol (CBD), a marijuana-derived compound, for children with severe epilepsy that hasn't improved with standard medications. The goal is to see if CBD can help reduce seizures in this difficult-to-treat group.
This study looks at how different brain scans (like MRI, PET, and EEG) can help find the exact spot where seizures start in people whose epilepsy hasn't been controlled by medicines. It aims to better understand drug-resistant epilepsy so doctors can plan more accurate treatments.
This trial tests if adding cannabidiol (CBD) to your child's current seizure medicines can reduce seizures. It uses a personalized approach to see if CBD works for each child.
This trial tests an oral cannabidiol medicine (Epidiolex) for children whose seizures are not controlled by other treatments. It aims to see if adding this drug can reduce seizure frequency.
This trial tests a new cannabidiol (CBD) liquid medicine for people with focal epilepsy (seizures that start in one part of the brain). It looks at whether the medication can help reduce seizures when added to your current seizure medications.
This trial tests a full-spectrum cannabis extract to see if it reduces seizures in people with tuberous sclerosis complex (TSC) whose seizures have not been controlled by other treatments. If it works, it could offer a new option for managing hard-to-treat epilepsy.
Hear when a new Drug Resistant Epilepsy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.